Institut National de la Santé et de la Recherche Médicale INSERM; National Institute of Health and Medical Research UMR 1033, University of Lyon, Lyon, France.
J Bone Miner Res. 2013 Aug;28(8):1760-70. doi: 10.1002/jbmr.1888.
Sclerostin is predominantly expressed by osteocytes. Serum sclerostin levels are positively correlated with areal bone mineral density (aBMD) measured by dual-energy X-ray absorptiometry (DXA) and bone microarchitecture assessed by high-resolution peripheral quantitative computed tomography (HR-pQCT) in small studies. We assessed the relation of serum sclerostin levels with aBMD and microarchitectural parameters based on HR-pQCT in 1134 men aged 20 to 87 years using multivariable models adjusted for confounders (age, body size, lifestyle, comorbidities, hormones regulating bone metabolism, muscle mass and strength). The apparent age-related increase in serum sclerostin levels was faster before the age of 63 years than afterward (0.43 SD versus 0.20 SD per decade). In 446 men aged ≤63 years, aBMD (spine, hip, whole body), trabecular volumetric BMD (Tb.vBMD), and trabecular number (Tb.N) at the distal radius and tibia were higher in the highest sclerostin quartile versus the three lower quartiles combined. After adjustment for aBMD, men in the highest sclerostin quartile had higher Tb.vBMD (mainly in the central compartment) and Tb.N at both skeletal sites (p < 0.05 to 0.001). In 688 men aged >63 years, aBMD was positively associated with serum sclerostin levels at all skeletal sites. Cortical vBMD (Ct.vBMD) and cortical thickness (Ct.Th) were lower in the first sclerostin quartile versus the three higher quartiles combined. Tb.vBMD increased across the sclerostin quartiles, and was associated with lower Tb.N and more heterogeneous trabecular distribution (higher Tb.Sp.SD) in men in the lowest sclerostin quartile. After adjustment for aBMD, men in the lowest sclerostin quartile had lower Tb.vBMD and Tb.N, but higher Tb.Sp.SD (p < 0.05 to 0.001) at both the skeletal sites. In conclusion, serum sclerostin levels in men are strongly positively associated with better bone microarchitectural parameters, mainly trabecular architecture, regardless of the potential confounders.
骨硬化蛋白主要由骨细胞表达。在一些小型研究中,血清骨硬化蛋白水平与双能 X 射线吸收法(DXA)测量的面积骨密度(aBMD)和高分辨率外周定量计算机断层扫描(HR-pQCT)评估的骨微结构呈正相关。我们使用多变量模型,根据 HR-pQCT 评估了 1134 名年龄在 20 至 87 岁的男性的血清骨硬化蛋白水平与 aBMD 和微结构参数的关系,并调整了混杂因素(年龄、体型、生活方式、合并症、调节骨代谢的激素、肌肉质量和力量)。与 63 岁以后相比,血清骨硬化蛋白水平的明显年龄相关性增加在 63 岁之前更快(每十年增加 0.43 SD 与 0.20 SD)。在 446 名年龄≤63 岁的男性中,与最低四分位组相比,最高四分位组的脊柱、髋部、全身骨密度(aBMD)、桡骨和胫骨远端的小梁体积骨密度(Tb.vBMD)和小梁数量(Tb.N)更高。调整 aBMD 后,最高四分位组的男性在两个骨骼部位的 Tb.vBMD(主要在中央区)和 Tb.N 更高(p<0.05 至 0.001)。在 688 名年龄>63 岁的男性中,所有骨骼部位的 aBMD 均与血清骨硬化蛋白水平呈正相关。与最高四分位组相比,第一四分位组的皮质体积骨密度(Ct.vBMD)和皮质厚度(Ct.Th)更低。随着骨硬化蛋白四分位的增加,Tb.vBMD 增加,与最低四分位组的较低 Tb.N 和更不均匀的小梁分布(更高的 Tb.Sp.SD)相关。调整 aBMD 后,最低四分位组的男性的 Tb.vBMD 和 Tb.N 较低,但 Tb.Sp.SD 较高(p<0.05 至 0.001),在两个骨骼部位均如此。总之,男性的血清骨硬化蛋白水平与更好的骨微结构参数呈强正相关,主要是小梁结构,无论潜在的混杂因素如何。